secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001437749-24-018249
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar CFO Kim Tsuchimoto retiring; Karthik Radhakrishnan appointed successor
------------------------------------------------------------------------------

- CFO Kim Tsuchimoto retires effective June 30, 2024 after 35+ years; remains on Board.
- Karthik Radhakrishnan appointed CFO, principal accounting and financial officer effective July 1, 2024.
- Radhakrishnan receives $384,800 annual salary, 35% target bonus, and options for 125,000 shares vesting over 4 years.
- Radhakrishnan has over 20 years experience; previously CFO of Opexa Therapeutics, founder of Titania Partners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924018249/0001437749-24-018249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924018249/mnpr20240523c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-018249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer